Xenetic Biosciences reported its second-quarter 2026 financial results. Royalty revenue for the three months ended June 30, 2026, increased approximately 12% to $0.7 million, compared to approximately $0.6 million for the comparable prior-year period. Net loss for the quarter was approximately $0.9 million, compared to approximately $0.7 million for the same period in 2025. The company ended the second quarter with approximately $6.5 million in cash and cash equivalents, down from approximately $7.9 million as of December 31, 2025.
Xenetic Biosciences IncNet loss widened to $0.9M from $0.7M and cash fell to $6.5M from $7.9M.